Hepatic signal transducer and activator of transcription‐3 signalling drives early‐stage pancreatic cancer cachexia via suppressed ketogenesis

Background Patients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both quality of life and survival. Although advanced cachexia is associated with inflammatory signalling and elevated muscle catabolism, the early events driving...

Full description

Saved in:
Bibliographic Details
Published inJournal of cachexia, sarcopenia and muscle Vol. 15; no. 3; pp. 975 - 988
Main Authors Arneson‐Wissink, Paige C., Mendez, Heike, Pelz, Katherine, Dickie, Jessica, Bartlett, Alexandra Q., Worley, Beth L., Krasnow, Stephanie M., Eil, Robert, Grossberg, Aaron J.
Format Journal Article
LanguageEnglish
Published Germany John Wiley & Sons, Inc 01.06.2024
John Wiley and Sons Inc
Wiley
Subjects
Online AccessGet full text
ISSN2190-5991
2190-6009
2190-6009
DOI10.1002/jcsm.13466

Cover

Loading…
Abstract Background Patients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both quality of life and survival. Although advanced cachexia is associated with inflammatory signalling and elevated muscle catabolism, the early events driving wasting are poorly defined. During periods of nutritional scarcity, the body relies on hepatic ketogenesis to generate ketone bodies, and lipid metabolism via ketogenesis is thought to protect muscle from catabolizing during nutritional scarcity. Methods We developed an orthotopic mouse model of early PDAC cachexia in 12‐week‐old C57BL/6J mice. Murine pancreatic cancer cells (KPC) were orthotopically implanted into the pancreas of wild‐type, IL‐6−/−, and hepatocyte STAT3−/− male and female mice. Mice were subject to fasting, 50% food restriction, ad libitum feeding or ketogenic diet interventions. We measured longitudinal body composition by EchoMRI, body mass and food intake. At the endpoint, we measured tissue mass, tissue gene expression by quantitative real‐time polymerase chain reaction, whole‐body calorimetry, circulating hormone levels, faecal protein and lipid content, hepatic lipid content and ketogenic response to medium‐chain fatty acid bolus. We assessed muscle atrophy in vivo and C2C12 myotube atrophy in vitro. Results Pre‐cachectic PDAC mice did not preserve gastrocnemius muscle mass during 3‐day food restriction (−13.1 ± 7.7% relative to food‐restricted sham, P = 0.0117) and displayed impaired fatty acid oxidation during fasting, resulting in a hypoketotic state (ketogenic response to octanoate bolus, −83.0 ± 17.3%, P = 0.0328; Hmgcs2 expression, −28.3 ± 7.6%, P = 0.0004). PDAC human patients display impaired fasting ketones (−46.9 ± 7.1%, P < 0.0001) and elevated circulating interleukin‐6 (IL‐6) (12.4 ± 16.5‐fold increase, P = 0.0001). IL‐6−/− PDAC mice had improved muscle mass (+35.0 ± 3.9%, P = 0.0031) and ketogenic response (+129.4 ± 44.4%, P = 0.0033) relative to wild‐type PDAC mice. Hepatocyte‐specific signal transducer and activator of transcription 3 (STAT3) deletion prevented muscle loss (+9.3 ± 4.0%, P = 0.009) and improved fasting ketone levels (+52.0 ± 43.3%, P = 0.018) in PDAC mice. Without affecting tumour growth, a carbohydrate‐free diet improved tibialis anterior myofibre diameter (+16.5 ± 3.5%, P = 0.0089), circulating ketone bodies (+333.0 ± 117.6%, P < 0.0001) and Hmgcs2 expression (+106.5 ± 36.1%, P < 0.0001) in PDAC mice. Ketone supplementation protected muscle against PDAC‐induced atrophy in vitro (+111.0 ± 17.6%, P < 0.0001 myofibre diameter). Conclusions In early PDAC cachexia, muscle vulnerability to wasting is dependent on inflammation‐driven metabolic reprogramming in the liver. PDAC suppresses lipid β‐oxidation and impairs ketogenesis in the liver, which is reversed in genetically modified mouse models deficient in IL‐6/STAT3 signalling or through ketogenic diet supplementation. This work establishes a direct link between skeletal muscle homeostasis and hepatic metabolism. Dietary and anti‐inflammatory interventions that restore ketogenesis may be a viable preventative approach for pre‐cachectic patients with pancreatic cancer.
AbstractList Abstract Background Patients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both quality of life and survival. Although advanced cachexia is associated with inflammatory signalling and elevated muscle catabolism, the early events driving wasting are poorly defined. During periods of nutritional scarcity, the body relies on hepatic ketogenesis to generate ketone bodies, and lipid metabolism via ketogenesis is thought to protect muscle from catabolizing during nutritional scarcity. Methods We developed an orthotopic mouse model of early PDAC cachexia in 12‐week‐old C57BL/6J mice. Murine pancreatic cancer cells (KPC) were orthotopically implanted into the pancreas of wild‐type, IL‐6−/−, and hepatocyte STAT3−/− male and female mice. Mice were subject to fasting, 50% food restriction, ad libitum feeding or ketogenic diet interventions. We measured longitudinal body composition by EchoMRI, body mass and food intake. At the endpoint, we measured tissue mass, tissue gene expression by quantitative real‐time polymerase chain reaction, whole‐body calorimetry, circulating hormone levels, faecal protein and lipid content, hepatic lipid content and ketogenic response to medium‐chain fatty acid bolus. We assessed muscle atrophy in vivo and C2C12 myotube atrophy in vitro. Results Pre‐cachectic PDAC mice did not preserve gastrocnemius muscle mass during 3‐day food restriction (−13.1 ± 7.7% relative to food‐restricted sham, P = 0.0117) and displayed impaired fatty acid oxidation during fasting, resulting in a hypoketotic state (ketogenic response to octanoate bolus, −83.0 ± 17.3%, P = 0.0328; Hmgcs2 expression, −28.3 ± 7.6%, P = 0.0004). PDAC human patients display impaired fasting ketones (−46.9 ± 7.1%, P < 0.0001) and elevated circulating interleukin‐6 (IL‐6) (12.4 ± 16.5‐fold increase, P = 0.0001). IL‐6−/− PDAC mice had improved muscle mass (+35.0 ± 3.9%, P = 0.0031) and ketogenic response (+129.4 ± 44.4%, P = 0.0033) relative to wild‐type PDAC mice. Hepatocyte‐specific signal transducer and activator of transcription 3 (STAT3) deletion prevented muscle loss (+9.3 ± 4.0%, P = 0.009) and improved fasting ketone levels (+52.0 ± 43.3%, P = 0.018) in PDAC mice. Without affecting tumour growth, a carbohydrate‐free diet improved tibialis anterior myofibre diameter (+16.5 ± 3.5%, P = 0.0089), circulating ketone bodies (+333.0 ± 117.6%, P < 0.0001) and Hmgcs2 expression (+106.5 ± 36.1%, P < 0.0001) in PDAC mice. Ketone supplementation protected muscle against PDAC‐induced atrophy in vitro (+111.0 ± 17.6%, P < 0.0001 myofibre diameter). Conclusions In early PDAC cachexia, muscle vulnerability to wasting is dependent on inflammation‐driven metabolic reprogramming in the liver. PDAC suppresses lipid β‐oxidation and impairs ketogenesis in the liver, which is reversed in genetically modified mouse models deficient in IL‐6/STAT3 signalling or through ketogenic diet supplementation. This work establishes a direct link between skeletal muscle homeostasis and hepatic metabolism. Dietary and anti‐inflammatory interventions that restore ketogenesis may be a viable preventative approach for pre‐cachectic patients with pancreatic cancer.
Patients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both quality of life and survival. Although advanced cachexia is associated with inflammatory signalling and elevated muscle catabolism, the early events driving wasting are poorly defined. During periods of nutritional scarcity, the body relies on hepatic ketogenesis to generate ketone bodies, and lipid metabolism via ketogenesis is thought to protect muscle from catabolizing during nutritional scarcity. We developed an orthotopic mouse model of early PDAC cachexia in 12-week-old C57BL/6J mice. Murine pancreatic cancer cells (KPC) were orthotopically implanted into the pancreas of wild-type, IL-6 , and hepatocyte STAT3 male and female mice. Mice were subject to fasting, 50% food restriction, ad libitum feeding or ketogenic diet interventions. We measured longitudinal body composition by EchoMRI, body mass and food intake. At the endpoint, we measured tissue mass, tissue gene expression by quantitative real-time polymerase chain reaction, whole-body calorimetry, circulating hormone levels, faecal protein and lipid content, hepatic lipid content and ketogenic response to medium-chain fatty acid bolus. We assessed muscle atrophy in vivo and C2C12 myotube atrophy in vitro. Pre-cachectic PDAC mice did not preserve gastrocnemius muscle mass during 3-day food restriction (-13.1 ± 7.7% relative to food-restricted sham, P = 0.0117) and displayed impaired fatty acid oxidation during fasting, resulting in a hypoketotic state (ketogenic response to octanoate bolus, -83.0 ± 17.3%, P = 0.0328; Hmgcs2 expression, -28.3 ± 7.6%, P = 0.0004). PDAC human patients display impaired fasting ketones (-46.9 ± 7.1%, P < 0.0001) and elevated circulating interleukin-6 (IL-6) (12.4 ± 16.5-fold increase, P = 0.0001). IL-6 PDAC mice had improved muscle mass (+35.0 ± 3.9%, P = 0.0031) and ketogenic response (+129.4 ± 44.4%, P = 0.0033) relative to wild-type PDAC mice. Hepatocyte-specific signal transducer and activator of transcription 3 (STAT3) deletion prevented muscle loss (+9.3 ± 4.0%, P = 0.009) and improved fasting ketone levels (+52.0 ± 43.3%, P = 0.018) in PDAC mice. Without affecting tumour growth, a carbohydrate-free diet improved tibialis anterior myofibre diameter (+16.5 ± 3.5%, P = 0.0089), circulating ketone bodies (+333.0 ± 117.6%, P < 0.0001) and Hmgcs2 expression (+106.5 ± 36.1%, P < 0.0001) in PDAC mice. Ketone supplementation protected muscle against PDAC-induced atrophy in vitro (+111.0 ± 17.6%, P < 0.0001 myofibre diameter). In early PDAC cachexia, muscle vulnerability to wasting is dependent on inflammation-driven metabolic reprogramming in the liver. PDAC suppresses lipid β-oxidation and impairs ketogenesis in the liver, which is reversed in genetically modified mouse models deficient in IL-6/STAT3 signalling or through ketogenic diet supplementation. This work establishes a direct link between skeletal muscle homeostasis and hepatic metabolism. Dietary and anti-inflammatory interventions that restore ketogenesis may be a viable preventative approach for pre-cachectic patients with pancreatic cancer.
BackgroundPatients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both quality of life and survival. Although advanced cachexia is associated with inflammatory signalling and elevated muscle catabolism, the early events driving wasting are poorly defined. During periods of nutritional scarcity, the body relies on hepatic ketogenesis to generate ketone bodies, and lipid metabolism via ketogenesis is thought to protect muscle from catabolizing during nutritional scarcity.MethodsWe developed an orthotopic mouse model of early PDAC cachexia in 12-week-old C57BL/6J mice. Murine pancreatic cancer cells (KPC) were orthotopically implanted into the pancreas of wild-type, IL-6−/−, and hepatocyte STAT3−/− male and female mice. Mice were subject to fasting, 50% food restriction, ad libitum feeding or ketogenic diet interventions. We measured longitudinal body composition by EchoMRI, body mass and food intake. At the endpoint, we measured tissue mass, tissue gene expression by quantitative real-time polymerase chain reaction, whole-body calorimetry, circulating hormone levels, faecal protein and lipid content, hepatic lipid content and ketogenic response to medium-chain fatty acid bolus. We assessed muscle atrophy in vivo and C2C12 myotube atrophy in vitro.ResultsPre-cachectic PDAC mice did not preserve gastrocnemius muscle mass during 3-day food restriction (−13.1 ± 7.7% relative to food-restricted sham, P = 0.0117) and displayed impaired fatty acid oxidation during fasting, resulting in a hypoketotic state (ketogenic response to octanoate bolus, −83.0 ± 17.3%, P = 0.0328; Hmgcs2 expression, −28.3 ± 7.6%, P = 0.0004). PDAC human patients display impaired fasting ketones (−46.9 ± 7.1%, P < 0.0001) and elevated circulating interleukin-6 (IL-6) (12.4 ± 16.5-fold increase, P = 0.0001). IL-6−/− PDAC mice had improved muscle mass (+35.0 ± 3.9%, P = 0.0031) and ketogenic response (+129.4 ± 44.4%, P = 0.0033) relative to wild-type PDAC mice. Hepatocyte-specific signal transducer and activator of transcription 3 (STAT3) deletion prevented muscle loss (+9.3 ± 4.0%, P = 0.009) and improved fasting ketone levels (+52.0 ± 43.3%, P = 0.018) in PDAC mice. Without affecting tumour growth, a carbohydrate-free diet improved tibialis anterior myofibre diameter (+16.5 ± 3.5%, P = 0.0089), circulating ketone bodies (+333.0 ± 117.6%, P < 0.0001) and Hmgcs2 expression (+106.5 ± 36.1%, P < 0.0001) in PDAC mice. Ketone supplementation protected muscle against PDAC-induced atrophy in vitro (+111.0 ± 17.6%, P < 0.0001 myofibre diameter).ConclusionsIn early PDAC cachexia, muscle vulnerability to wasting is dependent on inflammation-driven metabolic reprogramming in the liver. PDAC suppresses lipid β-oxidation and impairs ketogenesis in the liver, which is reversed in genetically modified mouse models deficient in IL-6/STAT3 signalling or through ketogenic diet supplementation. This work establishes a direct link between skeletal muscle homeostasis and hepatic metabolism. Dietary and anti-inflammatory interventions that restore ketogenesis may be a viable preventative approach for pre-cachectic patients with pancreatic cancer.
Background Patients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both quality of life and survival. Although advanced cachexia is associated with inflammatory signalling and elevated muscle catabolism, the early events driving wasting are poorly defined. During periods of nutritional scarcity, the body relies on hepatic ketogenesis to generate ketone bodies, and lipid metabolism via ketogenesis is thought to protect muscle from catabolizing during nutritional scarcity. Methods We developed an orthotopic mouse model of early PDAC cachexia in 12‐week‐old C57BL/6J mice. Murine pancreatic cancer cells (KPC) were orthotopically implanted into the pancreas of wild‐type, IL‐6−/−, and hepatocyte STAT3−/− male and female mice. Mice were subject to fasting, 50% food restriction, ad libitum feeding or ketogenic diet interventions. We measured longitudinal body composition by EchoMRI, body mass and food intake. At the endpoint, we measured tissue mass, tissue gene expression by quantitative real‐time polymerase chain reaction, whole‐body calorimetry, circulating hormone levels, faecal protein and lipid content, hepatic lipid content and ketogenic response to medium‐chain fatty acid bolus. We assessed muscle atrophy in vivo and C2C12 myotube atrophy in vitro. Results Pre‐cachectic PDAC mice did not preserve gastrocnemius muscle mass during 3‐day food restriction (−13.1 ± 7.7% relative to food‐restricted sham, P = 0.0117) and displayed impaired fatty acid oxidation during fasting, resulting in a hypoketotic state (ketogenic response to octanoate bolus, −83.0 ± 17.3%, P = 0.0328; Hmgcs2 expression, −28.3 ± 7.6%, P = 0.0004). PDAC human patients display impaired fasting ketones (−46.9 ± 7.1%, P < 0.0001) and elevated circulating interleukin‐6 (IL‐6) (12.4 ± 16.5‐fold increase, P = 0.0001). IL‐6−/− PDAC mice had improved muscle mass (+35.0 ± 3.9%, P = 0.0031) and ketogenic response (+129.4 ± 44.4%, P = 0.0033) relative to wild‐type PDAC mice. Hepatocyte‐specific signal transducer and activator of transcription 3 (STAT3) deletion prevented muscle loss (+9.3 ± 4.0%, P = 0.009) and improved fasting ketone levels (+52.0 ± 43.3%, P = 0.018) in PDAC mice. Without affecting tumour growth, a carbohydrate‐free diet improved tibialis anterior myofibre diameter (+16.5 ± 3.5%, P = 0.0089), circulating ketone bodies (+333.0 ± 117.6%, P < 0.0001) and Hmgcs2 expression (+106.5 ± 36.1%, P < 0.0001) in PDAC mice. Ketone supplementation protected muscle against PDAC‐induced atrophy in vitro (+111.0 ± 17.6%, P < 0.0001 myofibre diameter). Conclusions In early PDAC cachexia, muscle vulnerability to wasting is dependent on inflammation‐driven metabolic reprogramming in the liver. PDAC suppresses lipid β‐oxidation and impairs ketogenesis in the liver, which is reversed in genetically modified mouse models deficient in IL‐6/STAT3 signalling or through ketogenic diet supplementation. This work establishes a direct link between skeletal muscle homeostasis and hepatic metabolism. Dietary and anti‐inflammatory interventions that restore ketogenesis may be a viable preventative approach for pre‐cachectic patients with pancreatic cancer.
Patients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both quality of life and survival. Although advanced cachexia is associated with inflammatory signalling and elevated muscle catabolism, the early events driving wasting are poorly defined. During periods of nutritional scarcity, the body relies on hepatic ketogenesis to generate ketone bodies, and lipid metabolism via ketogenesis is thought to protect muscle from catabolizing during nutritional scarcity.BACKGROUNDPatients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both quality of life and survival. Although advanced cachexia is associated with inflammatory signalling and elevated muscle catabolism, the early events driving wasting are poorly defined. During periods of nutritional scarcity, the body relies on hepatic ketogenesis to generate ketone bodies, and lipid metabolism via ketogenesis is thought to protect muscle from catabolizing during nutritional scarcity.We developed an orthotopic mouse model of early PDAC cachexia in 12-week-old C57BL/6J mice. Murine pancreatic cancer cells (KPC) were orthotopically implanted into the pancreas of wild-type, IL-6-/-, and hepatocyte STAT3-/- male and female mice. Mice were subject to fasting, 50% food restriction, ad libitum feeding or ketogenic diet interventions. We measured longitudinal body composition by EchoMRI, body mass and food intake. At the endpoint, we measured tissue mass, tissue gene expression by quantitative real-time polymerase chain reaction, whole-body calorimetry, circulating hormone levels, faecal protein and lipid content, hepatic lipid content and ketogenic response to medium-chain fatty acid bolus. We assessed muscle atrophy in vivo and C2C12 myotube atrophy in vitro.METHODSWe developed an orthotopic mouse model of early PDAC cachexia in 12-week-old C57BL/6J mice. Murine pancreatic cancer cells (KPC) were orthotopically implanted into the pancreas of wild-type, IL-6-/-, and hepatocyte STAT3-/- male and female mice. Mice were subject to fasting, 50% food restriction, ad libitum feeding or ketogenic diet interventions. We measured longitudinal body composition by EchoMRI, body mass and food intake. At the endpoint, we measured tissue mass, tissue gene expression by quantitative real-time polymerase chain reaction, whole-body calorimetry, circulating hormone levels, faecal protein and lipid content, hepatic lipid content and ketogenic response to medium-chain fatty acid bolus. We assessed muscle atrophy in vivo and C2C12 myotube atrophy in vitro.Pre-cachectic PDAC mice did not preserve gastrocnemius muscle mass during 3-day food restriction (-13.1 ± 7.7% relative to food-restricted sham, P = 0.0117) and displayed impaired fatty acid oxidation during fasting, resulting in a hypoketotic state (ketogenic response to octanoate bolus, -83.0 ± 17.3%, P = 0.0328; Hmgcs2 expression, -28.3 ± 7.6%, P = 0.0004). PDAC human patients display impaired fasting ketones (-46.9 ± 7.1%, P < 0.0001) and elevated circulating interleukin-6 (IL-6) (12.4 ± 16.5-fold increase, P = 0.0001). IL-6-/- PDAC mice had improved muscle mass (+35.0 ± 3.9%, P = 0.0031) and ketogenic response (+129.4 ± 44.4%, P = 0.0033) relative to wild-type PDAC mice. Hepatocyte-specific signal transducer and activator of transcription 3 (STAT3) deletion prevented muscle loss (+9.3 ± 4.0%, P = 0.009) and improved fasting ketone levels (+52.0 ± 43.3%, P = 0.018) in PDAC mice. Without affecting tumour growth, a carbohydrate-free diet improved tibialis anterior myofibre diameter (+16.5 ± 3.5%, P = 0.0089), circulating ketone bodies (+333.0 ± 117.6%, P < 0.0001) and Hmgcs2 expression (+106.5 ± 36.1%, P < 0.0001) in PDAC mice. Ketone supplementation protected muscle against PDAC-induced atrophy in vitro (+111.0 ± 17.6%, P < 0.0001 myofibre diameter).RESULTSPre-cachectic PDAC mice did not preserve gastrocnemius muscle mass during 3-day food restriction (-13.1 ± 7.7% relative to food-restricted sham, P = 0.0117) and displayed impaired fatty acid oxidation during fasting, resulting in a hypoketotic state (ketogenic response to octanoate bolus, -83.0 ± 17.3%, P = 0.0328; Hmgcs2 expression, -28.3 ± 7.6%, P = 0.0004). PDAC human patients display impaired fasting ketones (-46.9 ± 7.1%, P < 0.0001) and elevated circulating interleukin-6 (IL-6) (12.4 ± 16.5-fold increase, P = 0.0001). IL-6-/- PDAC mice had improved muscle mass (+35.0 ± 3.9%, P = 0.0031) and ketogenic response (+129.4 ± 44.4%, P = 0.0033) relative to wild-type PDAC mice. Hepatocyte-specific signal transducer and activator of transcription 3 (STAT3) deletion prevented muscle loss (+9.3 ± 4.0%, P = 0.009) and improved fasting ketone levels (+52.0 ± 43.3%, P = 0.018) in PDAC mice. Without affecting tumour growth, a carbohydrate-free diet improved tibialis anterior myofibre diameter (+16.5 ± 3.5%, P = 0.0089), circulating ketone bodies (+333.0 ± 117.6%, P < 0.0001) and Hmgcs2 expression (+106.5 ± 36.1%, P < 0.0001) in PDAC mice. Ketone supplementation protected muscle against PDAC-induced atrophy in vitro (+111.0 ± 17.6%, P < 0.0001 myofibre diameter).In early PDAC cachexia, muscle vulnerability to wasting is dependent on inflammation-driven metabolic reprogramming in the liver. PDAC suppresses lipid β-oxidation and impairs ketogenesis in the liver, which is reversed in genetically modified mouse models deficient in IL-6/STAT3 signalling or through ketogenic diet supplementation. This work establishes a direct link between skeletal muscle homeostasis and hepatic metabolism. Dietary and anti-inflammatory interventions that restore ketogenesis may be a viable preventative approach for pre-cachectic patients with pancreatic cancer.CONCLUSIONSIn early PDAC cachexia, muscle vulnerability to wasting is dependent on inflammation-driven metabolic reprogramming in the liver. PDAC suppresses lipid β-oxidation and impairs ketogenesis in the liver, which is reversed in genetically modified mouse models deficient in IL-6/STAT3 signalling or through ketogenic diet supplementation. This work establishes a direct link between skeletal muscle homeostasis and hepatic metabolism. Dietary and anti-inflammatory interventions that restore ketogenesis may be a viable preventative approach for pre-cachectic patients with pancreatic cancer.
Author Dickie, Jessica
Krasnow, Stephanie M.
Worley, Beth L.
Bartlett, Alexandra Q.
Mendez, Heike
Eil, Robert
Arneson‐Wissink, Paige C.
Pelz, Katherine
Grossberg, Aaron J.
AuthorAffiliation 5 Cancer Early Detection Advanced Research Center Oregon Health & Science University Portland OR USA
1 Brenden‐Colson Center for Pancreatic Care Oregon Health & Science University Portland OR USA
3 Division of Oncological Sciences, Knight Cancer Institute Oregon Health & Science University Portland OR USA
2 Division of Surgical Oncology, Department of Surgery, Knight Cancer Institute Oregon Health & Science University Portland OR USA
4 Department of Radiation Medicine Oregon Health & Science University Portland OR USA
AuthorAffiliation_xml – name: 1 Brenden‐Colson Center for Pancreatic Care Oregon Health & Science University Portland OR USA
– name: 3 Division of Oncological Sciences, Knight Cancer Institute Oregon Health & Science University Portland OR USA
– name: 4 Department of Radiation Medicine Oregon Health & Science University Portland OR USA
– name: 2 Division of Surgical Oncology, Department of Surgery, Knight Cancer Institute Oregon Health & Science University Portland OR USA
– name: 5 Cancer Early Detection Advanced Research Center Oregon Health & Science University Portland OR USA
Author_xml – sequence: 1
  givenname: Paige C.
  orcidid: 0000-0002-2706-9652
  surname: Arneson‐Wissink
  fullname: Arneson‐Wissink, Paige C.
  organization: Oregon Health & Science University
– sequence: 2
  givenname: Heike
  surname: Mendez
  fullname: Mendez, Heike
  organization: Oregon Health & Science University
– sequence: 3
  givenname: Katherine
  surname: Pelz
  fullname: Pelz, Katherine
  organization: Oregon Health & Science University
– sequence: 4
  givenname: Jessica
  surname: Dickie
  fullname: Dickie, Jessica
  organization: Oregon Health & Science University
– sequence: 5
  givenname: Alexandra Q.
  surname: Bartlett
  fullname: Bartlett, Alexandra Q.
  organization: Oregon Health & Science University
– sequence: 6
  givenname: Beth L.
  surname: Worley
  fullname: Worley, Beth L.
  organization: Oregon Health & Science University
– sequence: 7
  givenname: Stephanie M.
  surname: Krasnow
  fullname: Krasnow, Stephanie M.
  organization: Oregon Health & Science University
– sequence: 8
  givenname: Robert
  surname: Eil
  fullname: Eil, Robert
  organization: Oregon Health & Science University
– sequence: 9
  givenname: Aaron J.
  orcidid: 0000-0003-4690-4948
  surname: Grossberg
  fullname: Grossberg, Aaron J.
  email: grossber@ohsu.edu
  organization: Oregon Health & Science University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38632714$$D View this record in MEDLINE/PubMed
BookMark eNp9kt1qFDEUgAep2Fp74wPIgDcibM3fJJkrKYvaSsUL9TpkkjPTrLPJmMys9s5HEB_RJzG7sxVbxEBIyPnOxyHnPCwOfPBQFI8xOsUIkRcrk9anmDLO7xVHBNdowRGqD_b3qq7xYXGS0grlxTjmFXpQHFLJKRGYHRU_z2HQozNlcp3XfTlG7ZOdDMRSe1tqM7qNHkMsQzvHTHTD6IL_9f0H3Sf1zneljW4DqQQd--scS6PuoBy0NxF2fpOvWWq0uYJvTpebvNM0DBFSAlt-hjF04CG59Ki43-o-wcn-PC4-vX71cXm-uHz_5mJ5drkwlSR8wTBUjErEK9HIlqNKNhXCBhhoQgw1AgvBCeMaCDKyEZabymohrWXCMFbT4-Ji9tqgV2qIbq3jtQraqd1DiJ3SMZfeg2ryX0kjW6CUMCZYU7XCsrbhhlrOCWTXy9k1TM0arAGfP6u_Jb0d8e5KdWGjMMZVFrJseLY3xPBlgjSqtUsG-l57CFNSFDFMKMN8iz69g67CFHMjthRngvJaykw9-bukP7Xc9D4DaAZMDClFaJVxo972NlfoeoWR2k6Y2k6Y2k1YTnl-J-XG-k8Yz_BX18P1f0j1dvnh3ZzzG_Wa5cA
CitedBy_id crossref_primary_10_3390_biomedicines13010210
crossref_primary_10_1186_s12944_024_02368_7
crossref_primary_10_12677_acm_2025_153803
crossref_primary_10_1097_CEJ_0000000000000918
crossref_primary_10_1016_j_tem_2024_12_005
Cites_doi 10.1152/ajpendo.00039.2012
10.1038/s41586-018-0235-7
10.1016/S1470-2045(10)70218-7
10.1016/j.pan.2018.11.002
10.1016/j.cmet.2023.05.008
10.3945/ajcn.2008.27273
10.1093/annonc/mdx369.158
10.1016/j.semcdb.2016.02.009
10.1093/ajcn/71.2.583
10.1002/jcsm.12899
10.1038/nrclinonc.2012.209
10.1111/febs.13709
10.3390/nu13093202
10.1056/NEJM197003192821209
10.1038/s41416-021-01301-4
10.1016/j.ccr.2005.04.023
10.1002/jcsm.12225
10.3389/fonc.2022.903157
10.1016/j.cmet.2015.09.005
10.1038/nm980
10.1007/s13539-012-0099-x
10.15430/JCP.2017.22.3.127
10.1042/bj1980227
10.1038/s41586-019-1004-y
10.1016/j.cmet.2016.10.010
10.1084/jem.20190450
10.1093/ajcn/nqy170
10.1002/jcsm.12554
10.1038/s41467-021-22361-3
10.1152/ajpregu.00716.2007
10.1016/j.celrep.2019.07.016
10.1186/s13395-020-00225-6
10.1002/jcsm.12377
10.1073/pnas.1714703115
10.3390/nu14071410
10.1172/JCI82204
10.1096/fj.13-230375
10.1001/jamaoncol.2015.6339
ContentType Journal Article
Copyright 2024 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC.
2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2024 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC.
– notice: 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1002/jcsm.13466
DatabaseName Wiley Online Library Open Access (WRLC)
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
Publicly Available Content Database

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Impaired ketogenesis drives early pancreatic cancer cachexia
EISSN 2190-6009
EndPage 988
ExternalDocumentID oai_doaj_org_article_b7148c8fe3324474b5f7d4fb6c3d662e
PMC11154744
38632714
10_1002_jcsm_13466
JCSM13466
Genre article
Journal Article
GrantInformation_xml – fundername: Oregon Health and Science University
  funderid: P30 CA069533; P30 CA069533 13S5
– fundername: Oregon Pancreas Tissue Registry
– fundername: National Cancer Institute
  funderid: K08CA245188; R37CA280692; R01CA264133
– fundername: Brenden‐Colson Center for Pancreatic Care
– fundername: NCI NIH HHS
  grantid: R37CA280692
– fundername: NCI NIH HHS
  grantid: R37 CA280692
– fundername: Brenden-Colson Center for Pancreatic Care
– fundername: NCI NIH HHS
  grantid: K08 CA245188
– fundername: NCI NIH HHS
  grantid: R01CA264133
– fundername: NCI NIH HHS
  grantid: P30 CA069533
– fundername: Oregon Health and Science University
  grantid: P30 CA069533 13S5
– fundername: NCI NIH HHS
  grantid: K08CA245188
– fundername: NCI NIH HHS
  grantid: R01 CA264133
GroupedDBID ---
0R~
1OC
24P
2VQ
4.4
40G
53G
5VS
7X7
8FI
8FJ
AAFWJ
AAKDD
AAMMB
AAZKR
ABUWG
ACCMX
ACXQS
ADBBV
ADKYN
ADRAZ
ADZMN
AEFGJ
AENEX
AFKRA
AFPKN
AGXDD
AHBYD
AHSBF
AIDQK
AIDYY
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMKLP
AOIJS
AVUZU
AZFZN
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
CCPQU
DIK
EBS
EJD
EMOBN
FYUFA
GROUPED_DOAJ
GX1
H13
HMCUK
HYE
IAO
IHR
INH
ITC
KQ8
M48
O9-
OK1
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RPM
RSV
SMD
SOJ
U2A
UKHRP
ZOVNA
AAHHS
AAYXX
ACCFJ
ADZOD
AEEZP
AEQDE
AIWBW
AJBDE
CITATION
ADINQ
ADPDF
CGR
CUY
CVF
ECM
EIF
M~E
NPM
OVD
OVEED
WIN
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c5826-41e54380657b8f6058b501ce4ea22c3c71776246ae20c8b7d6c5da78dd47c4493
IEDL.DBID 7X7
ISSN 2190-5991
2190-6009
IngestDate Wed Aug 27 01:24:32 EDT 2025
Thu Aug 21 18:33:48 EDT 2025
Thu Jul 10 19:12:29 EDT 2025
Fri Jul 25 07:53:27 EDT 2025
Wed Feb 19 01:58:36 EST 2025
Tue Jul 01 02:51:36 EDT 2025
Thu Apr 24 23:06:05 EDT 2025
Sun Jul 06 04:45:34 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords pancreatic cancer
interleukin‐6
ketogenesis
STAT3
cachexia
Language English
License Attribution
2024 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC.
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5826-41e54380657b8f6058b501ce4ea22c3c71776246ae20c8b7d6c5da78dd47c4493
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-2706-9652
0000-0003-4690-4948
OpenAccessLink https://www.proquest.com/docview/3064736988?pq-origsite=%requestingapplication%
PMID 38632714
PQID 3064736988
PQPubID 4370305
PageCount 14
ParticipantIDs doaj_primary_oai_doaj_org_article_b7148c8fe3324474b5f7d4fb6c3d662e
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11154744
proquest_miscellaneous_3041234164
proquest_journals_3064736988
pubmed_primary_38632714
crossref_citationtrail_10_1002_jcsm_13466
crossref_primary_10_1002_jcsm_13466
wiley_primary_10_1002_jcsm_13466_JCSM13466
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate June 2024
PublicationDateYYYYMMDD 2024-06-01
PublicationDate_xml – month: 06
  year: 2024
  text: June 2024
PublicationDecade 2020
PublicationPlace Germany
PublicationPlace_xml – name: Germany
– name: Heidelberg
– name: Hoboken
PublicationTitle Journal of cachexia, sarcopenia and muscle
PublicationTitleAlternate J Cachexia Sarcopenia Muscle
PublicationYear 2024
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Wiley
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
– name: Wiley
References 2009; 89
2017; 8
2023; 35
2013; 4
2013; 27
2021; 124
2017; 28
2018; 108
2019; 10
2015; 125
1970; 282
2017; 22
2016; 54
2019; 567
2019; 19
2000; 71
2011; 12
2020; 11
2020; 10
2012; 303
2016; 283
2004; 10
2021; 13
2021; 12
2016; 2
2014; 2
2013; 10
2018; 558
2021; 218
2018; 115
2015; 22
1981; 198
2019; 28
2022; 12
2005; 7
2022; 14
2008; 294
2016; 24
e_1_2_8_28_1
e_1_2_8_29_1
e_1_2_8_24_1
e_1_2_8_25_1
e_1_2_8_26_1
e_1_2_8_27_1
e_1_2_8_3_1
e_1_2_8_2_1
e_1_2_8_5_1
e_1_2_8_4_1
e_1_2_8_7_1
e_1_2_8_6_1
e_1_2_8_9_1
e_1_2_8_8_1
Chen I (e_1_2_8_13_1) 2017; 28
e_1_2_8_20_1
e_1_2_8_21_1
e_1_2_8_23_1
e_1_2_8_40_1
e_1_2_8_17_1
e_1_2_8_18_1
e_1_2_8_39_1
e_1_2_8_19_1
e_1_2_8_36_1
e_1_2_8_14_1
e_1_2_8_35_1
e_1_2_8_15_1
e_1_2_8_38_1
e_1_2_8_16_1
e_1_2_8_37_1
Shukla SK (e_1_2_8_22_1) 2014; 2
e_1_2_8_32_1
e_1_2_8_10_1
e_1_2_8_31_1
e_1_2_8_11_1
e_1_2_8_34_1
e_1_2_8_12_1
e_1_2_8_33_1
e_1_2_8_30_1
39723721 - J Cachexia Sarcopenia Muscle. 2025 Feb;16(1):e13687. doi: 10.1002/jcsm.13687
References_xml – volume: 71
  start-page: 583
  year: 2000
  end-page: 589
  article-title: Weight loss and elevated gluconeogenesis from alanine in lung cancer patients
  publication-title: Am J Clin Nutr
– volume: 22
  start-page: 789
  year: 2015
  end-page: 798
  article-title: A smartphone app reveals erratic diurnal eating patterns in humans that can be modulated for health benefits
  publication-title: Cell Metab
– volume: 13
  start-page: 3202
  year: 2021
  article-title: Ketogenic diets in pancreatic cancer and associated cachexia: cellular mechanisms and clinical perspectives
  publication-title: Nutrients
– volume: 4
  start-page: 55
  year: 2013
  end-page: 61
  article-title: Nutrition impact symptoms in advanced cancer patients: frequency and specific interventions, a case–control study
  publication-title: J Cachexia Sarcopenia Muscle
– volume: 558
  start-page: 600
  year: 2018
  end-page: 604
  article-title: Altered exocrine function can drive adipose wasting in early pancreatic cancer
  publication-title: Nature
– volume: 22
  start-page: 127
  year: 2017
  end-page: 134
  article-title: Rationale, feasibility and acceptability of ketogenic diet for cancer treatment
  publication-title: J Cancer Prev
– volume: 10
  year: 2020
  article-title: A novel transplantable model of lung cancer‐associated tissue loss and disrupted muscle regeneration
  publication-title: Skeletal Muscle
– volume: 125
  start-page: 4447
  year: 2015
  end-page: 4462
  article-title: Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver
  publication-title: J Clin Invest
– volume: 303
  start-page: E410
  year: 2012
  end-page: E421
  article-title: JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL‐6 and in experimental cancer cachexia
  publication-title: Am J Physiol‐Endocrinol Metab
– volume: 283
  start-page: 3002
  year: 2016
  end-page: 3015
  article-title: The JAK/STAT pathway in obesity and diabetes
  publication-title: FEBS J
– volume: 24
  start-page: 672
  year: 2016
  end-page: 684
  article-title: Tumor‐induced IL‐6 reprograms host metabolism to suppress anti‐tumor immunity
  publication-title: Cell Metab
– volume: 108
  start-page: 857
  year: 2018
  end-page: 867
  article-title: Effects of 3‐hydroxybutyrate and free fatty acids on muscle protein kinetics and signaling during LPS‐induced inflammation in humans: anticatabolic impact of ketone bodies
  publication-title: Am J Clin Nutr
– volume: 12
  start-page: 2259
  year: 2021
  end-page: 2261
  article-title: Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2021
  publication-title: J Cachexia Sarcopenia Muscle
– volume: 28
  year: 2017
  article-title: PACTO: a single center, randomized, phase II study of the combination of nab‐paclitaxel and gemcitabine with or without tocilizumab, an IL‐6R inhibitor, as first‐line treatment in patients with locally advanced or metastatic pancreatic cancer
  publication-title: Ann Oncol
– volume: 89
  start-page: 1173
  year: 2009
  end-page: 1179
  article-title: A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole‐body energy demands
  publication-title: Am J Clin Nutr
– volume: 12
  start-page: 489
  year: 2011
  end-page: 495
  article-title: Definition and classification of cancer cachexia: an international consensus
  publication-title: Lancet Oncol
– volume: 115
  start-page: E743
  year: 2018
  end-page: E752
  article-title: Fenofibrate prevents skeletal muscle loss in mice with lung cancer
  publication-title: Proc Natl Acad Sci
– volume: 282
  start-page: 668
  year: 1970
  end-page: 675
  article-title: Starvation in man
  publication-title: N Engl J Med
– volume: 2
  start-page: 782
  year: 2016
  end-page: 789
  article-title: Association of body composition with survival and locoregional control of radiotherapy‐treated head and neck squamous cell carcinoma
  publication-title: JAMA Oncol
– volume: 10
  start-page: 168
  year: 2004
  end-page: 174
  article-title: Role of STAT‐3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo
  publication-title: Nat Med
– volume: 11
  start-page: 973
  year: 2020
  end-page: 996
  article-title: Ketone bodies attenuate wasting in models of atrophy
  publication-title: J Cachexia Sarcopenia Muscle
– volume: 28
  start-page: 1612
  year: 2019
  end-page: 1622.e4
  article-title: Modeling human cancer‐induced cachexia
  publication-title: Cell Rep
– volume: 124
  start-page: 1623
  year: 2021
  end-page: 1636
  article-title: Pancreatic cancer cachexia: three dimensions of a complex syndrome
  publication-title: Br J Cancer
– volume: 294
  start-page: R393
  year: 2008
  end-page: R401
  article-title: Interleukin‐6 and cachexia in mice
  publication-title: Am J Physiol Regul Integr Comp Physiol
– volume: 567
  start-page: 249
  year: 2019
  end-page: 252
  article-title: Hepatocytes direct the formation of a pro‐metastatic niche in the liver
  publication-title: Nature
– volume: 198
  start-page: 227
  year: 1981
  end-page: 230
  article-title: Effects of liver damage on ketone‐body production and nitrogen balance in starved rats
  publication-title: Biochem J
– volume: 19
  start-page: 80
  year: 2019
  end-page: 87
  article-title: Circulating interleukin‐6 is associated with disease progression, but not cachexia in pancreatic cancer
  publication-title: Pancreatology
– volume: 12
  year: 2021
  article-title: Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia
  publication-title: Nat Commun
– volume: 8
  start-page: 824
  year: 2017
  end-page: 838
  article-title: Establishment and characterization of a novel murine model of pancreatic cancer cachexia
  publication-title: J Cachexia Sarcopenia Muscle
– volume: 35
  year: 2023
  article-title: Ketogenic diet promotes tumor ferroptosis but induces relative corticosterone deficiency that accelerates cachexia
  publication-title: Cell Metab
– volume: 2
  start-page: 1
  year: 2014
  end-page: 19
  article-title: Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia
  publication-title: Cancer Metab
– volume: 10
  start-page: 90
  year: 2013
  end-page: 99
  article-title: Understanding the mechanisms and treatment options in cancer cachexia
  publication-title: Nat Rev Clin Oncol
– volume: 14
  start-page: 1410
  year: 2022
  article-title: The influence of ketone bodies on circadian processes regarding appetite, sleep and hormone release: a systematic review of the literature
  publication-title: Nutrients
– volume: 218
  year: 2021
  article-title: Tumor‐derived IL‐6 and trans‐signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia
  publication-title: J Exp Med
– volume: 27
  start-page: 3572
  year: 2013
  end-page: 3582
  article-title: Cancer‐ and endotoxin‐induced cachexia require intact glucocorticoid signaling in skeletal muscle
  publication-title: FASEB J
– volume: 7
  start-page: 469
  year: 2005
  end-page: 483
  article-title: Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice
  publication-title: Cancer Cell
– volume: 10
  start-page: 378
  year: 2019
  end-page: 390
  article-title: MyD88 signalling is critical in the development of pancreatic cancer cachexia
  publication-title: J Cachexia Sarcopenia Muscle
– volume: 12
  start-page: 12
  year: 2022
  article-title: Systemic ketone replacement does not improve survival or cancer cachexia in mice with lung cancer
  publication-title: Front Oncol
– volume: 54
  start-page: 28
  year: 2016
  end-page: 41
  article-title: STAT3 in the systemic inflammation of cancer cachexia
  publication-title: Semin Cell Dev Biol
– ident: e_1_2_8_10_1
  doi: 10.1152/ajpendo.00039.2012
– ident: e_1_2_8_20_1
  doi: 10.1038/s41586-018-0235-7
– ident: e_1_2_8_7_1
  doi: 10.1016/S1470-2045(10)70218-7
– ident: e_1_2_8_8_1
  doi: 10.1016/j.pan.2018.11.002
– ident: e_1_2_8_35_1
  doi: 10.1016/j.cmet.2023.05.008
– ident: e_1_2_8_26_1
  doi: 10.3945/ajcn.2008.27273
– volume: 28
  year: 2017
  ident: e_1_2_8_13_1
  article-title: PACTO: a single center, randomized, phase II study of the combination of nab‐paclitaxel and gemcitabine with or without tocilizumab, an IL‐6R inhibitor, as first‐line treatment in patients with locally advanced or metastatic pancreatic cancer
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdx369.158
– ident: e_1_2_8_39_1
  doi: 10.1016/j.semcdb.2016.02.009
– ident: e_1_2_8_31_1
  doi: 10.1093/ajcn/71.2.583
– ident: e_1_2_8_40_1
  doi: 10.1002/jcsm.12899
– ident: e_1_2_8_2_1
  doi: 10.1038/nrclinonc.2012.209
– ident: e_1_2_8_33_1
  doi: 10.1111/febs.13709
– ident: e_1_2_8_37_1
  doi: 10.3390/nu13093202
– ident: e_1_2_8_4_1
  doi: 10.1056/NEJM197003192821209
– ident: e_1_2_8_6_1
  doi: 10.1038/s41416-021-01301-4
– ident: e_1_2_8_24_1
  doi: 10.1016/j.ccr.2005.04.023
– ident: e_1_2_8_16_1
  doi: 10.1002/jcsm.12225
– volume: 2
  start-page: 1
  year: 2014
  ident: e_1_2_8_22_1
  article-title: Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia
  publication-title: Cancer Metab
– ident: e_1_2_8_17_1
  doi: 10.3389/fonc.2022.903157
– ident: e_1_2_8_29_1
  doi: 10.1016/j.cmet.2015.09.005
– ident: e_1_2_8_32_1
  doi: 10.1038/nm980
– ident: e_1_2_8_5_1
  doi: 10.1007/s13539-012-0099-x
– ident: e_1_2_8_38_1
  doi: 10.15430/JCP.2017.22.3.127
– ident: e_1_2_8_21_1
  doi: 10.1042/bj1980227
– ident: e_1_2_8_28_1
  doi: 10.1038/s41586-019-1004-y
– ident: e_1_2_8_12_1
  doi: 10.1016/j.cmet.2016.10.010
– ident: e_1_2_8_11_1
  doi: 10.1084/jem.20190450
– ident: e_1_2_8_34_1
  doi: 10.1093/ajcn/nqy170
– ident: e_1_2_8_36_1
  doi: 10.1002/jcsm.12554
– ident: e_1_2_8_3_1
  doi: 10.1038/s41467-021-22361-3
– ident: e_1_2_8_9_1
  doi: 10.1152/ajpregu.00716.2007
– ident: e_1_2_8_14_1
  doi: 10.1016/j.celrep.2019.07.016
– ident: e_1_2_8_15_1
  doi: 10.1186/s13395-020-00225-6
– ident: e_1_2_8_19_1
  doi: 10.1002/jcsm.12377
– ident: e_1_2_8_23_1
  doi: 10.1073/pnas.1714703115
– ident: e_1_2_8_30_1
  doi: 10.3390/nu14071410
– ident: e_1_2_8_27_1
  doi: 10.1172/JCI82204
– ident: e_1_2_8_18_1
  doi: 10.1096/fj.13-230375
– ident: e_1_2_8_25_1
  doi: 10.1001/jamaoncol.2015.6339
– reference: 39723721 - J Cachexia Sarcopenia Muscle. 2025 Feb;16(1):e13687. doi: 10.1002/jcsm.13687
SSID ssj0000461650
Score 2.364833
Snippet Background Patients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both quality of life...
Patients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both quality of life and...
BackgroundPatients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both quality of life...
Abstract Background Patients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 975
SubjectTerms Animals
Body fat
cachexia
Cachexia - etiology
Cachexia - metabolism
Cell Line, Tumor
Diet, Ketogenic
Disease Models, Animal
Female
Food
Glucose
Humans
Immunoassay
interleukin‐6
ketogenesis
Ketone Bodies - metabolism
Laboratory animals
Liver
Liver - metabolism
Magnetic resonance imaging
Male
Metabolism
Mice
Musculoskeletal system
Nutrition research
Original
Pancreatic cancer
Pancreatic Neoplasms - complications
Pancreatic Neoplasms - metabolism
Plasma
Signal Transduction
STAT3
STAT3 Transcription Factor - metabolism
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQHhAXxJvAgozgAlLYxM_kCCtW1UrlAivtLfJjspRHuupjxZGfgPiJ_BJmnDS0YgUXDlWqeqI4nvHMN_X4M2PPUM3eRx_zFnyRK1eK3EWrcmilqIV2hfb0h_70rZmcqONTfbp11BfVhPX0wP3AHXiLgD1ULUgM_coqr1sbVetNkNEYAeR9MeZtJVPJBytTmnQ8q6C90hpR0MhNKg4-huWXl6VUiRrxdzRKpP2XIc0_Cya3gWyKREc32PUBQvJXfddvsivQ3WJXp8Mi-W32YwJUJh041Wag4IrCUUQVLrjrIqedDBeUavN527dtHMfPb9_lcBNtUudxQZy0HIgDGdsQR54BR-_RA83AA1nMAi-o-K8zxy_ws1yfp9JaiPwTrOZn5Epnyzvs5OjN-8NJPhy9kAeNCUeuStDERW-09VVLS6deF2UABU6IIAMmgehFlXEgilB5G03Q0dkqRmWDUrW8y_a6eQf3GY8W3Qa0UBkVVB1jLRFBgsCxdK6tiyJjzzcqaMLAS07HY3xuekZl0ZC6mqSujD0dZc97No5LpV6TJkcJYtBOP6BdNYNdNf-yq4ztb-ygGab1sqF0zUpTV1XGnozNOCFplcV1MF-TjEI0gDhXZexebzZjT2RlpMAHZ6zaMaidru62dLMPifS7JN4kq_DWF8n2_vL-zfHhu2n69uB_jMRDdk0gkuvr4_bZ3mqxhkeIxFb-cZp0vwB9SzV3
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9NAEF6VIiEuiDeGghbBBSQXe5_2ASGoqKJK4QKRerP25RAodnGSqvwJfjMzaztqRNSDFSs7q9g7j_0mu_sNIa9BzdZ669M62CwVJmep8VqkoeasZNJk0uIf-tMvajITJ6fydI-M9TuHAVzuTO2wntSsOzu8_P3nAzj8-4FA9N0Pt_x1mHOh1A1yE2YkjQ46HWB-jMhC5SoWa2V4cloCJtowlV7tvjU3RQr_Xbjz_-2TV2FtnJeO75I7A6CkH3sLuEf2QnOf3JoOS-YPyN9JwE3TjuJODRBc4eTkQaEdNY2neK7hAhNv2tZ92xhGUj50wQPr1HfIT0sD8iGngCjngUIc6SGnow5tp4MPMIHLhaEXcC3X53GTbfD0Z1i1cwyqi-VDMjv-_O1okg5FGFInIfVIRR4kstIrqW1R4yKqlVnuggiGMccdpIMQT4UygWWusNorJ73RhfdCOyFK_ojsN20TnhDqNQSQUIdCCSdK70sOWDIwGEdj6jLLEvJmHP7KDQzlWCjjrOq5lVmFqqqiqhLyaiN73vNy7JT6hFrcSCCXdvyi7ebV4JqV1ZASuqIOHMCl0MLKWntRW-W4V4qFhByMNlCN9llh4qa5KosiIS83zeCauN5imtCuUUYALgDEKxLyuDeZzZPwQnEGP5yQYsuYth51u6VZfI_03zkyKGkBXd9Gu7vm_auTo6_TePf0-pd4Rm4zQGv9HrgDsr_q1uE5oK2VfRFd6R8ydyty
  priority: 102
  providerName: Scholars Portal
– databaseName: Wiley Online Library Open Access (WRLC)
  dbid: 24P
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Li9RAEG7WFcSL-Da6SoteFOIm_UzAiy4uw8KIoAt7C_3KOD6SJZlZPPoTxJ_oL7Gqk8k6uAgehgzT1SST6qr-qrvqa0Kegpqt9dandbBZKkzOUuO1SEPNWcmkyaTFBf35WzU7Fkcn8mSHvNzUwgz8ENOCG1pG9Ndo4Mb2--ekoZ9c__VFzoVSl8hlrK1F5nwm3k0rLEglruIRrQzrpSUgoYmflO2fd9-akSJx_0Vo8--kyT_BbJyNDq-TayOMpK8Gvd8gO6G5Sa7Mx43yW-TnLGCqtKOYnwGCK5ySPKixo6bxFKsZzjDcpm09tG2cx6_vP_jYCQvVqe-Ql5YG5EGGNsCSi0DBgwxg01GHo6aDCyj_29LQM_j069OYXhs8_RxW7QLd6bK_TY4P33w4mKXj8QupkxB0pCIPEvnoldS2qHH71Mosd0EEw5jjDgJB8KRCmcAyV1jtlZPe6MJ7oZ0QJb9Ddpu2CfcI9RpcR6hDoYQTpfclBxQZGLxLY-oyyxLybKOCyo3c5HhExpdqYFVmFaqriupKyJNJ9nRg5LhQ6jVqcpJAFu34Q9stqtEoK6shGHRFHTjASqGFlbX2orbKca8UCwnZ24yDajTtvsKQTXNVFkVCHk_NYJS402Ka0K5RRgAiAKwrEnJ3GDbTk_BCcQY3TkixNaC2HnW7pVl-jMTfOXInaQFdn8ex94__Xx0dvJ_Hb_f_R_gBucoAtQ25cHtkd9Wtw0NAXSv7KBrXb5ipLgQ
  priority: 102
  providerName: Wiley-Blackwell
Title Hepatic signal transducer and activator of transcription‐3 signalling drives early‐stage pancreatic cancer cachexia via suppressed ketogenesis
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjcsm.13466
https://www.ncbi.nlm.nih.gov/pubmed/38632714
https://www.proquest.com/docview/3064736988
https://www.proquest.com/docview/3041234164
https://pubmed.ncbi.nlm.nih.gov/PMC11154744
https://doaj.org/article/b7148c8fe3324474b5f7d4fb6c3d662e
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELfYJiFeEN8ERmUELyCFpbZjJ0-ITZuqSZ0mYFLfIn-lKx9JSdqJv4K_mTsnzaiY9tC0ii9qkjuffz6ff0fIW1CzMc64uPQmiYUes1g7JWJfcpazVCepwYD-9ExOLsTpLJ31Abe2T6vc-MTgqF1tMUZ-gEhZcZln2cflrxirRuHqal9CY4fsIXUZpnSpmRpiLEgmLkORVoY7plPAQgNDKTv4ZtufH8ZcBILE6zEpUPffhDf_T5v8F86G8ejkAbnfA0n6qdP8Q3LHV4_I3Wm_VP6Y_Jl4TJa2FDM0QHCFg5IDRTZUV47ifoYrnHDTuuzaNu4j5v0luFGdugZ5aalHHuQYkOTcU_AfHdS01KLNNPAFqv-90PQKPu16GZJrvaPf_aqeozNdtE_Ixcnx16NJ3BdfiG0KU45YjH2KbPQyVSYrcfHUpMnYeuE1Y5ZbmAaCHxVSe5bYzCgnbeq0ypwTygqR86dkt6or_5xQp8Bx-NJnUliRO5dzwJCewXvUusyTJCLvNq-_sD0zORbI-FF0nMqsQFUVQVUReTPILjs-jhulDlGLgwRyaIcTdTMv-i5ZGAVTQZuVngOoFEqYtFROlEZa7qRkPiL7Gxso-o7dFtdmGJHXQzN0SVxn0ZWv1ygjAA8A0hURedaZzHAnPJOcwR9HJNsypq1b3W6pFpeB9nuMzElKwKXvg93d8vzF6dGXafj14vaHeEnuMUBpXe7bPtldNWv_ClDWyozIDhPno9ChRmTv8Pjs_PMoRCzgOBXZXwSzLZQ
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLamTgJeEHcCA4yAB5DCUtuJ0weE2NjUXVoh2KS9Bd9SukFSehnwJ_gp_EbOcS6jYtrbHqpWtaNczsnn79jH3yHkOZhZa6ttmDsdhUJ1WaisFKHLOeuxWEWxxgn9wTDpH4rdo_hohfxp9sJgWmWDiR6obWlwjnwdmbLkSS9N306-h1g1CldXmxIalVvsuV8_IGSbvdl5D_Z9wdj21sFmP6yrCoQmBi4diq6LUWY9iaVOc1wV1HHUNU44xZjhBuIbAAiRKMcik2ppExNbJVNrhTRCoPgSQP6q4BDKdMjqxtbww8d2VgflyxNfFpbhHu0Y2FericrWj83s2-suF16S8WwU9MUCzmO4_ydq_kug_Qi4fYNcr6krfVf52k2y4opb5MqgXpy_TX73HaZnG4o5IdBxjsOgBdeZUlVYijsoTjHEp2VetTWAFfL6ENwaT-0UlXCpQ-XlELjryFFArIrcGmrQS6fwBc72c6zoKXxmi4lP53WWnrh5OUL4Hs_ukMNLMcxd0inKwt0n1EqAKpe7NBFG9KztcWCtjsFzVCrvRVFAXjaPPzO1FjqW5PiaVSrOLENTZd5UAXnW9p1UCiDn9tpAK7Y9ULXb_1FOR1kNApmWEHyaNHccaKyQQse5tCLXieE2SZgLyFrjA1kNJbPszPED8rRtBhDAlR1VuHKBfQQwEODWIiD3Kpdpr4SnCWdw4oCkS860dKnLLcX4ixca76JWkxRw6Cvvdxfcf7a7-Wngfz24-CaekKv9g8F-tr8z3HtIrjHgiFXm3RrpzKcL9wg43lw_rl8sSj5f9rv8FywMZc8
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3ZbtQwFLWqIlW8IHYCBYyAB5BCEy9x5gEhaBlNW6ZCgkrzlsZLplMgGWYp8BN8EF_Hvc5SRlR960M00dhRlnt9fGxfn0vIMzCz1lbbsHA6CkUeszC3SoSu4KzHZB5JjRP6w4NkcCj2RnK0Rv60e2EwrLLFRA_UtjI4R76FTFnxpAcDtqIJi_i4038z_R5iBilcaW3TadQusu9-_YDh2_z17g7Y-jlj_feftwdhk2EgNBJ4dShiJ1FyPZFKpwWuEGoZxcYJlzNmuIGxDoCFSHLHIpNqZRMjba5Sa4UyQqAQE8D_FcVljG1MjVQ3v4NC5olPEMtwt7YEHtapo7KtEzP_9irmwosznvWHPm3AeVz3_5DNf6m07wv718m1hsTSt7XX3SBrrrxJNobNMv0t8nvgMFDbUIwOgYoL7BAtONGM5qWluJfiFAf7tCrqsha6Qt5cgpvkqZ2hJi51qMEcAosdOwrYVdNcQw366wx-wO1-TnJ6Csd8OfWBvc7SL25RjRHIJ_Pb5PBSzHKHrJdV6e4RahWAlitcmggjetb2OPBXx-A75nnRi6KAvGg_f2YaVXRMzvE1q_WcWYamyrypAvK0qzuttUDOrfUOrdjVQP1u_0c1G2cNHGRawTDUpIXjQGiFEloWyopCJ4bbJGEuIJutD2QNqMyzsyYQkCddMcABrvHkpauWWEcAFwGWLQJyt3aZ7kl4mnAGNw5IuuJMK4-6WlJOjr3keIyqTUrApS-9313w_tne9qehP7t_8Us8JhvQgrMPuwf7D8hVBmSxDsHbJOuL2dI9BLK30I98q6Lk6LKb8V_AVWif
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hepatic+signal+transducer+and+activator+of+transcription-3+signalling+drives+early-stage+pancreatic+cancer+cachexia+via+suppressed+ketogenesis&rft.jtitle=Journal+of+cachexia%2C+sarcopenia+and+muscle&rft.au=Arneson-Wissink%2C+Paige+C&rft.au=Mendez%2C+Heike&rft.au=Pelz%2C+Katherine&rft.au=Dickie%2C+Jessica&rft.date=2024-06-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=2190-5991&rft.eissn=2190-6009&rft.volume=15&rft.issue=3&rft.spage=975&rft.epage=988&rft_id=info:doi/10.1002%2Fjcsm.13466&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2190-5991&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2190-5991&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2190-5991&client=summon